Clinical Trials: Phase I/II Trial of Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

Sponsor and Collaborators

Dana-Farber Cancer Institute

Wyeth

Millennium Pharmaceuticals, Inc.

Contact

Irene Ghobrial, MD

617-632-4198

[email protected]

Principal Investigator

Irene Ghobrial, MD Dana-Farber Cancer Institute

ClinicalTrials.gov Identifier